|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01EX18
|
|
gptkbp:brand
|
Balversa
|
|
gptkbp:CASNumber
|
1346242-81-6
|
|
gptkbp:chemicalFormula
|
C25H30N6O2
|
|
gptkbp:contraindication
|
hypersensitivity to erdafitinib
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
59 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Erdafitinib
|
|
gptkbp:indication
|
locally advanced urothelial carcinoma
metastatic urothelial carcinoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
FGFR inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP2C9
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
eye
fatigue
dry mouth
hyperphosphatemia
stomatitis
nail disorder
|
|
gptkbp:target
|
gptkb:FGFR3
gptkb:FGFR1
gptkb:FGFR4
gptkb:FGFR2
|
|
gptkbp:usedFor
|
gptkb:urothelial_carcinoma
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:CD332
gptkb:CD333
|
|
gptkbp:bfsLayer
|
7
|